Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease-Reference-Cited by-同舟云学术

Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease

Published:2017-07-06 Issue:44 Volume:8 Page:76129-76140
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Li Liubing¹,Wang Qian¹,Wen Xiaoting¹,Liu Chenxi¹,Wu Chanyuan¹,Yang Funing¹²,Zeng Xiaofeng¹,Li Yongzhe¹

Affiliation:

1. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China

2. Department of Medical Laboratory, The First Hospital of Jilin University, Changchun, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rapidly Progressive Interstitial Lung Disease With Pneumothorax and Pneumomediastinum Secondary to Amyopathic Dermatomyositis;Cureus;2023-12-19

2. Clinical risk factors in patients with interstitial lung disease associated with anti-MDA5 autoantibodies;Medicina Clínica;2023-12

3. Clinical risk factors in patients with interstitial lung disease associated with anti-MDA5 autoantibodies;Medicina Clínica (English Edition);2023-12

4. Clinical nomogram assisting in discrimination of juvenile dermatomyositis-associated interstitial lung disease;Respiratory Research;2023-11-16

5. Ulcérations cutanées, mélanodermie et dyspnée;La Revue de Médecine Interne;2023-02